Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490676 | 0.94 | SMN1; SMN2 (0.53) | SMN1; SMN2GID4KMT2ADRD4DPP4 | |
| SCHEMBL14192814 | 0.94 | SMN1; SMN2 (0.53) | SMN1; SMN2GID4KMT2ADRD4DPP4 | |
| Trifluoroacetic Acid SCHEMBL3215916 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2GID4MAPTRAB9APOLB | |
| Trifluoroacetic Acid SCHEMBL3220716 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2GID4KMT2AMAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL3207659 | 0.86 | NPC1 (0.57) | SMN1; SMN2GID4RAB9A | |
| Trifluoroacetic Acid SCHEMBL3223498 | 0.86 | NPC1 (0.57) | SMN1; SMN2GID4RAB9A | |
| Trifluoroacetic Acid SCHEMBL3210512 | 0.84 | HTR2B (0.43) | SMN1; SMN2GID4 | |
| Trifluoroacetic Acid SCHEMBL3209776 | 0.82 | GID4 (0.40) | SMN1; SMN2GID4POLB | |
| Trifluoroacetic Acid SCHEMBL3210455 | 0.82 | PIN1 (0.45) | SMN1; SMN2GID4KMT2ARAB9A | |
| SCHEMBL13490654 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2GID4MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | SMN1; SMN2 746/4885GID4 2961/4885KMT2A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.